Beijing Continent Pharmaceutical Co, Ltd.
Clinical trials sponsored by Beijing Continent Pharmaceutical Co, Ltd., explained in plain language.
-
New pill aims to tame liver scarring in hepatitis b
Disease control Recruiting nowThis study tests a drug called hydronidone in 150 adults with liver scarring caused by chronic hepatitis B. Participants take the capsules three times daily for 28 days. The main goal is to check for side effects and ensure the drug is safe. This is an early-phase trial, so it fo…
Phase: PHASE2 • Sponsor: Beijing Continent Pharmaceutical Co, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for lung injury: drug may repair radiation and immunotherapy damage
Disease control Recruiting nowThis study tests if the drug pirfenidone can help people with lung damage caused by radiation therapy (with or without immunotherapy). About 298 adults with certain cancers who received chest radiation will take pirfenidone or a placebo for 24 weeks. The goal is to see if the dru…
Phase: PHASE2, PHASE3 • Sponsor: Beijing Continent Pharmaceutical Co, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill aims to halt liver scarring in hepatitis b and fatty liver patients
Disease control Recruiting nowThis study tests a drug called hydronidone in 200 adults with liver fibrosis caused by chronic hepatitis B or fatty liver disease. Participants take three capsules three times daily for 28 days. The main goal is to check for side effects, not to measure how well the drug works.
Phase: PHASE2 • Sponsor: Beijing Continent Pharmaceutical Co, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New liver drug safety trial begins for hepatitis b scarring
Disease control Recruiting nowThis study tests a drug called hydronidone in 300 adults with liver scarring (fibrosis or cirrhosis) from chronic hepatitis B. Participants take the drug three times daily for 28 days to see if it is safe. The main goal is to track any side effects.
Phase: PHASE3 • Sponsor: Beijing Continent Pharmaceutical Co, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Can a lung fibrosis drug help miners breathe easier?
Disease control Recruiting nowThis Phase 3 trial tests whether pirfenidone capsules can improve lung function in 272 people with pneumoconiosis, a lung disease caused by inhaling dust. Participants take the drug or a placebo three times daily for a year. The main goal is to see if lung function (measured by F…
Phase: PHASE3 • Sponsor: Beijing Continent Pharmaceutical Co, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New injection shows promise for liver failure in early trial
Disease control Recruiting nowThis Phase 2 trial is testing an experimental drug called F573 in 97 people with acute liver failure or acute-on-chronic liver failure. Participants receive daily injections of F573 or a placebo for 7 days. The main goal is to check safety and side effects, while also looking at …
Phase: PHASE2 • Sponsor: Beijing Continent Pharmaceutical Co, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Kidney patients needed for Early-Stage drug safety study
Knowledge-focused Recruiting nowThis study tests a single dose of hydroxynidone capsules in 56 people with different levels of kidney function and healthy volunteers. The goal is to see how the drug moves through the body and if it is safe in people with kidney problems. Participants will have blood and urine t…
Phase: PHASE1 • Sponsor: Beijing Continent Pharmaceutical Co, Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
New pill for lung disease passes first safety check in healthy people
Knowledge-focused Recruiting nowThis early-stage study tests a new tablet called F230 in 136 healthy adults to see if it is safe and how the body processes it. The drug is designed to treat pulmonary hypertension, a serious lung condition. Researchers will also check if food changes how the drug works. This stu…
Phase: PHASE1 • Sponsor: Beijing Continent Pharmaceutical Co, Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC